Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
Author:
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
http://www.tandfonline.com/doi/pdf/10.4161/mabs.1.1.7509
Reference18 articles.
1. EGFR Antagonists in Cancer Treatment
2. Recent developments related to the EGFR as a target for cancer chemotherapy
3. ERBB receptors and cancer: the complexity of targeted inhibitors
4. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
5. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity
Cited by 188 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer;Pharmaceutics;2024-09-11
2. Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis;Current Cancer Drug Targets;2024-09
3. Nimotuzumab combined with radiotherapy+/- chemotherapy for definitive treatment of locally advanced squamous cell carcinoma of head and neck: a metanalysis of randomized controlled trials;Frontiers in Oncology;2024-06-13
4. A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma;Cancer Letters;2024-06
5. Concurrent nimotuzumab and intensity‐modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma;Cancer Science;2024-05-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3